IFNG and cancer: Using an IFN-γ gene signature predictive of response to blockade of the PD-1/PD-L1 axis, we found that DUX4-expressing cancers have statistically lower levels of IFN-γ activity (Figure 2—figure supplement 1B; Ayers et al., 2017).